



**Vita Life Sciences Limited**

ACN 003 190 421  
ABN 35 003 190 421

**Corporate Office**  
Suite 802, Level 8,  
1-5 Chalmers Crescent  
Mascot NSW 2020  
Australia  
T: 61 2 9545 2633  
F: 61 2 9545 1311  
vitalifesciences.com

17 June 2025

Market Announcements  
Australian Securities Exchange Ltd  
20 Bridge Street  
Sydney, NSW 2000

## GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the half year ending 30 June 2025:

**Sales: \$45.0m-\$46.0m** (H1 2024: \$39.5m)

**Pre-tax Profit: \$6.2m-6.7m** (H1 2024: \$6.0m)

The Company expects to deliver revenue growth of around 14–16% on the prior corresponding period (PCP), reflecting the strength of core markets, Australia, Malaysia and Singapore. The new distributor in China continues to successfully build sales, albeit sales to China will be lower than the PCP.

The Group continues to invest strategically in its brands, sales channels and marketing capabilities to drive market share gains and revenue growth. These investments are expensed and reflected in the Group's forecast 1<sup>st</sup> half pre-tax profit and are critical to strengthening our competitive position and unlocking long-term value across key markets.

Directors remain confident in building upon 1<sup>st</sup> half momentum in the 2<sup>nd</sup> half, as sales initiatives continue to gain traction. Overall, the Group remains focussed on its long-term strategy and remains committed to delivering sustainable growth and value for shareholders.

A handwritten signature in black ink, appearing to read 'Andrew O'Keefe'.

Andrew O'Keefe  
Managing Director

Email: [enquiries@vitalifesciences.com.au](mailto:enquiries@vitalifesciences.com.au)

For personal use only